Zura Bio (NASDAQ:ZURA) vs. Creative Medical Technology (NASDAQ:CELZ) Critical Contrast

Zura Bio (NASDAQ:ZURA) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Profitability

This table compares Zura Bio and Creative Medical Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-82.30%	-66.71%
Creative Medical Technology	N/A	-41.48%	-40.22%

Analyst Ratings

This is a summary of recent ratings and price targets for Zura Bio and Creative Medical Technology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	0	0	4	1	3.20
Creative Medical Technology	0	0	0	0	N/A

Zura Bio presently has a consensus price target of $16.40, indicating a potential upside of 395.47%. Given Zura Bio’s higher probable upside, equities analysts clearly believe Zura Bio is more favorable than Creative Medical Technology.

Valuation and Earnings

This table compares Zura Bio and Creative Medical Technology’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$69.24 million	N/A	N/A
Creative Medical Technology	$10,000.00	656.89	-$5.29 million	($3.71)	-1.30

Creative Medical Technology has higher revenue and earnings than Zura Bio.

Volatility and Risk

Zura Bio has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500.

Institutional & Insider Ownership

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 15.8% of Zura Bio shares are owned by company insiders. Comparatively, 3.3% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.